Prospective, Randomized, Pharmacological Intervention Study; Evaluating Effect of the Angiotensin II-receptor (AT1) Blocker Candesartan vs Placebo in Prevention of Trastuzumab-associated Cardiotoxicity in Patients Treated With Trastuzumab.
Phase of Trial: Phase III
Latest Information Update: 05 Dec 2014
At a glance
- Drugs Candesartan cilexetil (Primary)
- Indications Cardiovascular disorders
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 26 Mar 2014 Status changed from recruiting to completed as reported by European Clinical Trials Database.
- 29 Jul 2010 Additional trial location (USA) identified as reported by ClinicalTrials.gov.